Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive LY2216684 versus placebo in major depressive disorder partial responders to SSRI treatment
2010-021214-39Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edivoxetine in major depressive disorder (MDD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline to last visit in adjunctive treatment phase in MADRS total score. Started Nov 2010; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-021214-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021214-39.